Dfmo (** Generic (investigational) **)

Other Medications

EU Not submitted to EMA ES Not available 2 Clinical Trials

Description

DMFO is under investigation for its potential role in the treatment of colorectal cancer, particularly as a DNA hypomethylating agent. Its use is currently experimental and not approved by regulatory bodies like the FDA. It may be used in clinical trials to assess its efficacy and safety profile in patients with advanced or refractory colorectal cancer.

Mechanism of Action

DMFO acts as a DNA hypomethylating agent, inhibiting the activity of DNA methyltransferases and potentially reversing hypermethylation associated with cancer progression; it is thought to reactivate silenced tumor suppressor genes.

Side Effects

Hematological toxicity; gastrointestinal symptoms; fatigue; skin reactions

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07287917 Phase 1
Recruiting
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
United States
NCT05500508 Phase 1
Terminated
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
United States, Australia

Quick Info

Brand Name** Generic (investigational) **
CategoryOther Medications
EU EMA StatusNot submitted to EMA
ES Spain AccessNot available
Clinical Trials2
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
779 trials
Leucovorin
Other Medications
639 trials
Paclitaxel
Other Medications
53 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Trifluridine
Other Medications
47 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.